Nicotinamide and Nonmelanoma Skin Cancers
- 15 February 2022
- journal article
- editorial
- Published by Wolters Kluwer Health in Ophthalmic Plastic & Reconstructive Surgery
- Vol. 38 (3) , 304-305
Abstract
Oral nicotinamide supplementation may have the potential to reduce the incidence of non-melanoma skin cancers, and although currently unproven, given its favorable side effect profile, supplementation should be considered seriously, particularly in high-risk individuals.Keywords
This publication has 26 references indexed in Scilit:
- Nicotinamide enhances repair of ultraviolet radiation-induced DNA damage in human keratinocytes and ex vivo skinCarcinogenesis, 2013
- Smoking and the Risk of Nonmelanoma Skin CancerArchives of Dermatology, 2012
- Oral Nicotinamide Reduces Actinic Keratoses in Phase II Double-Blinded Randomized Controlled TrialsJournal of Investigative Dermatology, 2012
- Nicotinamide Prevents Ultraviolet Radiation‐induced Cellular Energy LossPhotochemistry and Photobiology, 2010
- Photoprotective effects of nicotinamidePhotochemical & Photobiological Sciences, 2010
- Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humansCarcinogenesis, 2008
- Cyclobutane pyrimidine dimer formation is a molecular trigger for solar-simulated ultraviolet radiation-induced suppression of memory immunity in humansPhotochemical & Photobiological Sciences, 2005
- European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetesThe Lancet, 2004
- Prevention of photoimmunosuppression and photocarcinogenesis by topical nicotinamideNutrition and Cancer, 1997
- The Use of Nicotinamide in the Prevention of Type 1 DiabetesAnnals of the New York Academy of Sciences, 1993